Search clinical trials for: Sodium glucose co-transporter 2 inhibitors

Total 116179 results

AstraZeneca
Bristol-Myers Squibb

Completed

Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients

Type 2 Diabetes

Czech Republic, Korea, Republic of, Hungary, Poland, Ukraine, Philippines, Thailand
AstraZeneca
Bristol-Myers Squibb

Suspended

Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone

Type 2 Diabetes

India
Ono Pharmaceutical Co. Ltd

Completed

ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

Taiwan
Esperion Therapeutics, Inc.
Medpace, Inc.

Completed

Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

Hypertension | Hypercholesterolemia

United States
Janssen Scientific Affairs, LLC

Completed

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

Hypertension | Diabetes Mellitus, Type 2

United States, Puerto Rico
University of Diyala

Completed

Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio

Type 2 Diabetes

Iraq
Mackay Memorial Hospital

Completed

Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial (ELUCIDATE)

Type 2 Diabetes Mellitus

Taiwan
Astellas Pharma Inc

Completed

A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients

Type 2 Diabetes Mellitus

Japan
AstraZeneca

Terminated

Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin

Type 2 Diabetes Mellitus

Thailand, Vietnam
Sanofi

Completed

A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

Type 2 Diabetes Mellitus

United States, Canada, Hungary, Slovakia
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Type 2 Diabetes Mellitus

United States, Bulgaria, Estonia, Hungary, Korea, Republic of, Poland, Romania, Slovakia, Ukraine, United Kingdom
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents (SOTA-INS)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czechia, France, Hungary, Slovakia, United Kingdom
Merck Sharp & Dohme LLC
Pfizer

Completed

A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)

Type 2 Diabetes Mellitus
AstraZeneca

Completed

A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients (DAPACARD)

Diabetes Mellitus Type 2

Finland, Sweden
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Astellas Pharma Inc

Completed

Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Type 2 Diabetes Mellitus
LG Chem

Completed

Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)

Type 2 Diabetes Mellitus

Korea, Republic of
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin (IMPRESSION)

Type 2 Diabetes Mellitus

Russian Federation
Merck Sharp & Dohme LLC
Pfizer

Completed

A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

Type 2 Diabetes Mellitus
LG Chem

Unknown

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

Type 2 Diabetes Mellitus

Korea, Republic of
University of Erlangen-Nürnberg Medical School

Completed

Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

Diabetes Mellitus Type 2

Germany
Astellas Pharma Inc

Completed

A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2

United States
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

Type 2 Diabetes Mellitus
Asan Medical Center
Samsung Medical Center; Astellas Pharma Korea, Inc.; Severance Hospital; Kyung...

Completed

Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin

Type 2 Diabetes Mellitus

Korea, Republic of
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
AstraZeneca
Bristol-Myers Squibb

Completed

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Terminated

Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Lexicon Pharmaceuticals

Completed

A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC
Pfizer

Active, not recruiting

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

Type 2 Diabetes Mellitus

United States, Belgium, Canada, Colombia, Costa Rica, Dominican Republic, France, Guatemala, Hungary, Israel, Italy, Malaysia, Mauritius, Mexico, Philippines, Poland, Russian Federation, Saudi Arabia, Turkey, Ukraine, United Arab... and more
Sanofi

Completed

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

Type 2 Diabetes Mellitus

China
Sanofi

Terminated

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise

Type 2 Diabetes Mellitus

China
Lexicon Pharmaceuticals
Sanofi

Terminated

Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (SOTA-BONE)

Type 2 Diabetes Mellitus

United States, Australia, Canada, Korea, Republic of, Mexico, New Zealand, Russian Federation, Taiwan
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin (SOTA-EMPA)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czechia, France, Italy, Latvia, Mexico, Russian Federation, Slovakia, Spain, United Kingdom

3

Subscribe